SEC Filing Summary: New York Mortgage Trust, Inc.
Business Context and Reporting Period
This Form 8-K was filed on January 6, 2010, by New York Mortgage Trust, Inc. (the "Company"). The report addresses a temporary failure to comply with Nasdaq listing requirements regarding independent directors and audit committee composition, followed by the appointment of a new director to restore compliance.
Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status.
Material Changes
- Resignation: Steven M. Abreu, an independent director and Audit Committee member, resigned effective December 21, 2009.
- Non-Compliance: From December 21, 2009, through January 11, 2010, the Company did not meet Nasdaq Listing Rule 5605 requirements for a majority of independent directors and a three-member independent audit committee.
- Regulatory Notice: On January 6, 2010, Nasdaq notified the Company of the non-compliance and granted a cure period until the earlier of the next annual shareholders' meeting or December 21, 2010.
- Appointment: On January 12, 2010, the Board appointed Daniel Osborne as a director and member of the Audit, Compensation, and Nominating and Corporate Governance Committees.
Outlook, Management Commentary, and Risks
Restoration of Compliance: The Company determined that Mr. Osborne qualifies as independent under Nasdaq rules. Consequently, the Company believes it has regained compliance with Listing Rule 5605 as of January 12, 2010.
Management Commentary: Mr. Osborne was selected to serve as the Chairman of the Audit Committee and as the "audit committee financial expert," concluding a six-month search. He will receive standard non-executive director fees.
Risks: The primary risk addressed was the potential delisting or failure to satisfy continued listing standards due to the vacancy on the Audit Committee. This risk was mitigated by the immediate appointment of Mr. Osborne.
Key Facts for Investor Verification
- Verify that Daniel Osborne's appointment as an independent director and Audit Committee Chairman has been formally accepted by Nasdaq to ensure continued listing status.
- Review the Company's definitive proxy statement (filed April 28, 2009) for details on director compensation applicable to Mr. Osborne.
- Confirm the Company's timeline for its next annual shareholders' meeting to understand the original cure period deadline.
- Assess the impact of the six-month vacancy in the Audit Committee Chair role on the Company's financial oversight during that period.